Comparing Upfront Payments among Multinational, Mid-Sized European, and Japanese Drug Firms
Executive Summary
Continuing our focus on the licensing styles of different types of in-licensors of biotechnology, this month looks at the upfront payments made to biotech partners by the top 10 multinational drug companies, mid-sized Europeans, and Japanese drug firms.